Management of type 2 diabetes mellitus and cardiovascular risk -: Lessons from intervention trials

被引:34
|
作者
Yki-Järvinen, H [1 ]
机构
[1] Univ Helsinki, Dept Med, Helsinki 00029, Finland
关键词
D O I
10.2165/00003495-200060050-00001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Although the diagnosis of type 2 (noninsulin-dependent) diabetes mellitus is made when blood glucose levels exceed values which increase the risk of microvascular complications, macrovascular disease is the major complication of type 2 diabetes mellitus. Both epidemiological and prospective data have demonstrated that treatment of hyperglycaemia is markedly effective in reducing the risk of microvascular disease but is less potent in reducing that of myocardial infarction, stroke and peripheral Vascular disease. Treatment of other cardiovascular risk factors, although by definition less prevalent than hyperglycaemia, appears to be more effective in preventing macrovascular disease than treatment of hyperglycaemia. In recent years, data from intervention trials have suggested that greater benefits with respect to the prevention of macrovascular disease can be achieved by effective treatment of hypertension and hypercholesterolaemia, and by the use of small doses of aspirin (acetylsalicylic acid) than by treating hyperglycaemia alone. On the other hand, the UK Prospective Diabetes Study (UKPDS), which examined the impact of intensive glucose and blood pressure (BP) control on micro- and macrovascular complications,is the only intervention trial to include only patients with type 2 diabetes mellitus. The UKPDS data, the epidemic increase in the number of patients with type 2 diabetes mellitus and their high cardiovascular risk have, however, initiated several new trials addressing, in particular, the possible benefits of treatment of the most common form of dyslipidaemia (high serum triglyceride and low high density lipoprotein cholesterol levels) in these patients. Type 2 diabetes mellitus is thus a disease associated with a high vascular risk, where the majority of patients need, and are likely to benefit from, pharmacological treatment of several cardiovascular risk factors provided treatment targets have not been achieved by life-style modification.
引用
收藏
页码:975 / 983
页数:9
相关论文
共 50 条
  • [21] CARDIOVASCULAR RISK AND TYPE 2 DIABETES MELLITUS RISK IN OBESE CHILDREN
    Maldonado, J.
    Rubio, N.
    Yafi, M.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2020, 22 : A238 - A238
  • [22] The impact of cardiovascular outcome trials on the choice of insulins in the management of type 2 diabetes mellitus: An expert review
    Rajput, Rajesh
    Mukherjee, Jagat Jyoti
    Ayyar, Vageesh S.
    Ghosal, Samit
    CLINICAL DIABETOLOGY, 2018, 7 (05): : 234 - 246
  • [23] Cardiovascular risk factors in patients with type 2 diabetes mellitus
    Carolina Vintimilla, Evelin
    Vintimilla Molina, Jhojana Rosati
    Carmendel Rocio Parra
    Martinez Santander, Diana Antonieta
    Martinez Santander, Carlos Jose
    del Rocio Andrade, Neida
    Cumbe Guerrero, Karla Maria
    Cardenas Heredia, Fredy Rosendo
    REVISTA LATINOAMERICANA DE HIPERTENSION, 2018, 13 (04): : 356 - 360
  • [24] Evaluation and Review of Strategies to Assess Cardiovascular Risk in Clinical Trials in Patients with Type 2 Diabetes Mellitus
    Marchenko, Olga
    Jiang, Qi
    Chakravarty, Aloka
    Ke, Chunlei
    Ma, Haijun
    Maca, Jeff
    Russek-Cohen, Estelle
    Sanchez-Kam, Matilde
    Zink, Richard C.
    Chuang-Stein, Christy
    STATISTICS IN BIOPHARMACEUTICAL RESEARCH, 2015, 7 (04): : 253 - 266
  • [25] Cardiovascular Risk in Children and Adolescents with Type 2 Diabetes Mellitus
    Prendergast, Christopher
    Gidding, Samuel S.
    CURRENT DIABETES REPORTS, 2014, 14 (02)
  • [26] Cardiovascular Risk in Children and Adolescents with Type 2 Diabetes Mellitus
    Christopher Prendergast
    Samuel S. Gidding
    Current Diabetes Reports, 2014, 14
  • [27] Reducing cardiovascular risk in patients with type 2 diabetes mellitus
    Nicholls, Stephen J.
    Ryden, Lars
    EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2010, 17 : S1 - S1
  • [28] Evidence of suboptimal management of cardiovascular risk in patients with type 2 diabetes mellitus and symptomatic atherosclerosis
    Brown, LC
    Johnson, JA
    Majumdar, SR
    Tsuyuki, RT
    McAlister, FA
    CANADIAN MEDICAL ASSOCIATION JOURNAL, 2004, 171 (10) : 1189 - 1192
  • [29] Nutritional management, skipping breakfast, glycemic control, and cardiovascular risk on type 2 diabetes mellitus
    Minari, T. Palotta
    Tacito, L. Bonalume
    Yugar, L. Buonalumi Tacito
    Rubio, T. Azevedo
    Pires, A. Carlos
    Cosenso-Martin, L. N.
    Vilela-Martin, J. F.
    Moreno, H.
    Yugar-Toledo, J. C.
    EUROPEAN HEART JOURNAL, 2024, 45
  • [30] The Clinical Implications of the CHICAGO Study for the Management of Cardiovascular Risk in Patients With Type 2 Diabetes Mellitus
    Polonsky, Tamar
    Mazzone, Theodore
    Davidson, Michael
    TRENDS IN CARDIOVASCULAR MEDICINE, 2009, 19 (03) : 94 - 99